Caxton Associates (New York)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,500
| Closed | -$1.64M | – | 657 |
|
|
2024
Q2 | $1.64M | Sell |
3,500
-2,269
| -39% | -$1.06M | 0.06% | 178 |
|
|
2024
Q1 | $2.41M | Sell |
5,769
-71,034
| -92% | -$29.7M | 0.14% | 102 |
|
|
2023
Q4 | $31.3M | Buy |
76,803
+71,624
| +1,383% | +$29.1M | 1.6% | 13 |
|
|
2023
Q3 | $1.8M | Buy |
5,179
+4,060
| +363% | +$1.41M | 0.25% | 67 |
|
|
2023
Q2 | $394K | Buy |
+1,119
| New | +$394K | 0.06% | 303 |
|
|
2023
Q1 | – | Sell |
-3,826
| Closed | -$1.1M | – | 636 |
|
|
2022
Q4 | $1.1M | Sell |
3,826
-1,232
| -24% | -$356K | 0.07% | 93 |
|
|
2022
Q3 | $1.46M | Buy |
5,058
+3,943
| +354% | +$1.14M | 0.2% | 41 |
|
|
2022
Q2 | $314K | Buy |
+1,115
| New | +$314K | 0.03% | 356 |
|
|
2022
Q1 | – | Sell |
-2,031
| Closed | -$446K | – | 693 |
|
|
2021
Q4 | $446K | Sell |
2,031
-2,396
| -54% | -$526K | 0.05% | 285 |
|
|
2021
Q3 | $803K | Buy |
+4,427
| New | +$803K | 0.09% | 109 |
|
|
2020
Q4 | – | Sell |
-2,961
| Closed | -$806K | – | 314 |
|
|
2020
Q3 | $806K | Sell |
2,961
-584
| -16% | -$159K | 0.08% | 57 |
|
|
2020
Q2 | $1.03M | Buy |
3,545
+2,375
| +203% | +$689K | 0.09% | 56 |
|
|
2020
Q1 | $278K | Sell |
1,170
-1,872
| -62% | -$445K | 0.05% | 270 |
|
|
2019
Q4 | $666K | Buy |
+3,042
| New | +$666K | 0.09% | 121 |
|
|
2017
Q4 | – | Sell |
-2,000
| Closed | -$304K | – | 483 |
|
|
2017
Q3 | $304K | Buy |
+2,000
| New | +$304K | 0.01% | 386 |
|